Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00904579|
Recruitment Status : Recruiting
First Posted : May 19, 2009
Last Update Posted : January 12, 2018
- Solid organ transplantation provides life-saving treatment for end-stage organ disease but is associated with an increased cancer risk because of the need for long-term immunosuppression
- End-stage renal disease (ESRD), the most common type of end-stage organ disease leading to transplant, is itself linked to increased risk for some cancers
- The role of immunosuppression and other factors causing cancer in this setting are not fully understood.
- To characterize cancer risk in transplant recipients and identify risk factors.
- To characterize risk for transmission of cancer from organ donors to recipients.
- To describe cancer risk in ESRD.
Eligibility: Patients are not required for this study. Data are gathered from existing databases of ESRD patients, organ transplant patients and cancer registries.
- Databases of 1) U.S. transplant recipients, donors and wait list candidates and 2) U.S. ESRD patients will be linked to multiple U.S. cancer registries to identify cancers in transplant recipients and ESRD patients.
- The spectrum of cancer risk in transplant recipients and ESRD patients will be evaluated in detail.
- The cancer risk in transplant recipients will be examined in relation to whether the donors had cancer.
- The proposed cancer risk factors (e.g., underlying medical condition, infection with cancer-causing viruses, immunosuppressive medications) documented in transplant and ESRD files will be studied for association with increased risk of particular types of cancer.
|Condition or disease|
|Immunocompromised Host Organ Transplantation Cancer|
|Study Type :||Observational|
|Estimated Enrollment :||1929901 participants|
|Official Title:||Cancer Risk in Solid Organ Transplant Recipients and End-Stage Renal Disease: The Transplant Cancer Match Study|
|Study Start Date :||July 1, 2006|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00904579
|Contact: Eric A Engels, M.D.||(301) firstname.lastname@example.org|
|United States, California|
|California Cancer Registry||Recruiting|
|Sacramento, California, United States, 95811|
|United States, Colorado|
|Colorado Cancer Registry||Recruiting|
|Denver, Colorado, United States, 12206|
|United States, Connecticut|
|Connecticut Cancer Registry||Recruiting|
|Hartford, Connecticut, United States, 06134|
|United States, Georgia|
|Georgia Cancer Registry||Recruiting|
|Atlanta, Georgia, United States, 30303|
|United States, Iowa|
|Iowa Cancer Registry||Recruiting|
|Iowa City, Iowa, United States, 52242|
|United States, Maryland|
|National Cancer Institute (NCI), 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: Eric Engels, M.D. 301-435-4722 email@example.com|
|United States, New Jersey|
|New Jersey Cancer Registry||Recruiting|
|New Brunswick, New Jersey, United States, 08901|
|United States, New York|
|New York Cancer Registry||Recruiting|
|Albany, New York, United States, 12206|
|United States, Washington|
|Seattle Cancer Registry||Recruiting|
|Seattle, Washington, United States, 98109|
|Principal Investigator:||Eric A Engels, M.D.||National Cancer Institute (NCI)|